Single-dose comparison of formoterol (Oxis®) Turbuhaler® 6 μg and formoterol Aerolizer® 12 μg in moderate to severe asthma: A randomised, crossover study

Pulmonary Pharmacology and Therapeutics

Volumn 15, Issue 4, 2002, Pages 369-374

  Schlimmer, Paul ^a  

^a Shg Kliniken Volklingen   (Germany)

Author keywords

Aerolizer; Asthma; Formoterol; Oxis; Turbuhaler

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; FORMOTEROL FUMARATE;

ADULT; AGED; AIRWAY CONDUCTANCE; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BLOOD PRESSURE; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEART RATE; HUMAN; LUNG FUNCTION; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036385624     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2002.0375     Document Type: Article

References (39)

1. NIH/NHLBI. International consensus report on diagnosis and treatment of asthma. National Heart, Lung and Blood Institute, National Institutes of Health. Publication no. 92-3091. Eur Respir J 1992; 5: 601-641.
2. Ernst P. Inhaled drug delivery: a practical guide to prescribing inhaler devices. Can Respir J 1998; 5: 180-183.
3. Fink J B. Metered-dose inhalers, dry powder inhalers and transitions. Respir Care 2000; 45: 623-635.
4. Epstein S W, Manning C P R, Ashley M Y, Corvey P N. Survey of the clinical use of pressurised aerosol inhalers. Can Med Assoc J 1979; 120: 813-816.
5. Löfdahl C-G, Andersson L, Carlsson L G, Friberg K, Hörnblad Y, Jemsby P et al. Lower nominal dose required of inhaled salbutamol via Turbohaler® compared with pressurized metered dose inhaler, for the same bronchodilating effect. Am J Respir Crit Care Med 1994; 149: A219.
6. Thorsson L, Edsbäcker S, Condrason T B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered dose inhaler (pMDI). Eur Respir J 1994; 7: 1839-1844.
7. Lipworth B J, Clark D J. Comparative lung delivery of salbutamol given via Turbuhaler® and Diskus® dry powder inhaler devices. Eur J Clin Pharmacol 1997; 53: 47-49.
8. Anderson G P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci 1993; 52: 2145-2160.
9. Molimard M, Naline E, Zhang Y, Le Gros V, Begaud B, Advenier C. Long- and short acting β2-adrenoceptor agonists: Interactions in human contracted bronchi. Eur Respir J 1998; 11: 583-588.
10. Politiek M J, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999; 13: 988-992.
11. Seberová E, Andersson A. Oxis® (formoterol given by Turbuhaler®) showed as rapid an onset of action as salbutamol given by pMDI. Respir Med 2000; 94: 607-611.
12. Malolepszy J, Böszörményi Nagy G, Selroos O, Larsson P, Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J 1998; 12 (Supp. 28): 323.
13. Rabe K F, Jörres R, Nowak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436-1441.
14. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489.
15. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®. Respir Med 1998; 92: 1017-1021.
16. Ind P, Börszörmenyl Nagy G, Pietinalho A, Siner R, Villasante C, Brander R et al. Formoterol 4.5 μg used as needed via Turbuhaler® was as safe and well tolerated as terbutaline 0.5 mg. Eur Respir J 1999; 14(Suppl 30): 148s.
17. O'Connor B, McSorley L C, Turbitt M L. Use of formoterol (Oxis®) Turbuhaler® as needed in moderate to severe asthma reduces the number of inhalers whilst maintaining effectiveness. J Allergy Clin Immunol 2001; 107(Part 2): A360.
18. Tattersfield A E, Löfdahl C-G, Postma D S, Eivindson A, Schreurs A G, Rasidakis A, Ekström T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257-261.
19. Kemp J P, Chervinsky H N. A randomized, double-blind, placebo-controlled, dose-response study with formoterol Turbohaler®. J Allergy Clin Immunol 1997; 99: A1343.
20. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichilova H, Skopova O. Formoterol in Turbuhaler® is faster and has a more beneficial ratio than salmeterol Diskhaler® in asthmatic children. Eur Respir J 1998; 12(Suppl 28): 87s.
21. Foradil® (Formoterol fumarate dihydrate). Prescribing information. Novartis, 2000.
22. Clauzel A M, Molimard M, Le Gros V, Lepere E, Febvre N, Michel F B. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients. J Investig Allergol Clin Immunol 1998; 8: 265-270.
23. Rosenborg J, Larsson P, Luts A, Oeberg G, Mardell C, Asking L, Axelsson M. Lung deposition of formoterol was greater after inhalation via the dry powder inhaler (DPI) Turbuhaler® than via the DPI Aerolizer®. Eur Resp J 1999; 14(Suppl 30): 62s.
24. Murphy S, Bleecker E R, Boushey H et al. Practical guide for the diagnosis and management of asthma: NIH Publication No 97-4053, October 1997.
25. British Guidelines on Asthma Management: 1995 review and position statement: Thorax 1997; 52(Suppl 1): 1-21.
26. Comment: Keeley D, Rees J. BMJ 1997; 314: 315-316
27. Jones B, Kenward MG. Design and analysis of cross-over trials. London: Chapman & Hall, 1990.
28. Thompson P J, Jenkins C, Ruffin R E, Mitchell C A, Holmes P W. Comparison of the efficacy of formoterol 12 μg bd via dry powder inhaler with salmeterol 50 μg bd via pressurised metered dose inhaler in moderate to severe asthmatics. Eur Respir J 1998; 12(Suppl 28): 324s.
29. Lötvall J, Persson G, Larsson P, Mardell C, Rosenborg J. Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice daily formoterol 12 μg (9 μg delivered). Eur Respir J 1997; 10(Suppl 25): 103s.
30. Tötterman K J, Huhti L, Sutinen E, Backman R, Pietinalho A, Falck M, Larsson P, Selroos O. Tolerability to high doses of formoterol and terbutaline via Turbuhaler® for 3 days in stable asthmatic patients. Eur Respir J 1998; 12: 573-579.
31. Lecaillon J B, Kaiser G, Palmisano M, Morgan J, Della Cioppa G. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil® dry powder inhalation via Aerolizer®. Eur J Clin Pharmacol 1999; 55: 131-138.
32. Lötvall J, Mellén A, Arvidsson P, Palmqvist M, Radielovic P, Kottakis J, Pfister P. Similar bronchodilation with formoterol delivered by Aerolizer or Turbuhaler. Can Respir J 1999; 6: 412-416.
33. Eliraz A, Ramirez-Rivera A, Ferranti P, Holzer R, Garcia JM, Turcotte C, Rapatz G, Pfister P, Overend T, Kottakis J. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 μg bid delivered by two different dry powder inhalers: differences in inhaler handling. Int J Clin Pract 2001; 55: 164-170.
34. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-1640.
35. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-381.
36. Pauwels R A, Löfdahl C-G, Postma D S, Tattersfiled A E, O'Byrne P, Barnes P J et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
37. Rees P J, Clark T J. The importance of particle size in response to inhaled bronchodilators. Eur J Respir Dis 1982; 63(Suppl 119): 73-78.
38. 3H) formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. Drug Metab Depos 1999; 27: 1104-1116.
39. Behling B, Matthys H. Comparison of efficacy and safety of formoterol with terbutaline in children with mild to moderate asthma. Eur Respir J 1999; 14(Suppl 30): 43s.